ArticleDrug design, development and therapy2025
Research Trends and Developments in Nanomaterials for Rheumatoid Arthritis: A Comprehensive Bibliometric Analysis.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global research trends and hotspot evolution of olfactory dysfunction from 2014 to 2024: a bibliometric analysis.Annals of medicine and surgery (2012) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatoid arthritis (RA) is one of the common diseases associated with job loss and disability. However, the existing diagnosis and treatment methods are limited by factors such as misdiagnosis, missed diagnosis, and toxic side effects. In recent years, remarkable progress has been made in applying nanomedicine for RA treatment. However, previous studies lack a systematic and comprehensive analysis of the development trajectory of nanomaterials in the diagnosis and treatment of RA, the contributions of key researchers, and the evolution of research focuses. This study aims to fill this gap by providing a detailed bibliometric analysis of the global research landscape on nanomaterial applications in RA diagnosis and treatment, highlighting the significance of this field in advancing therapeutic interventions and identifying future research directions. Methods: Relevant literature on the application of nanomaterials in RA treatment was searched in the Web of Science Core Collection (WoSCC) database from January 1, 1985 to December 31, 2023. VOSviewer, CiteSpace, "bibliometrix" R-package, and Microsoft Office Excel 2021 were used for bibliometric analysis to evaluate the number of publications, research hotspots, main researchers, and institutions. Results: A total of 524 articles were included, involving 33 countries or regions, 784 institutions, and 2751 authors, covering 19 disciplines, including biochemistry and molecular biology, chemistry, engineering, immunology, and materials science. Countries with the highest publication output were China, India, and the United States, with China and the United States having the closest cooperation. The University of California at San Diego and CHEN X were the most influential institutions and authors. Journal of Controlled Release had the highest publication output and emerged as the most influential journal in the field. In recent years, research hotspots of nanomaterials in RA included "dexamethasone", "micelle", and "diagnosis". Conclusion: This study is the first comprehensive bibliometric analysis of nanotechnology in RA application. It highlights the importance of nanomaterials in advancing RA diagnosis and treatment and provides a valuable reference for future research. By identifying key research trends, influential contributors, and emerging hotspots, this analysis offers actionable insights for researchers to build upon, ultimately driving innovation and improving therapeutic outcomes in the field of nanomedicine for RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.